# RNN 2nd Gen Model Zoetis Inc. Pharmaceutical preparations

Stock predictor AI models:
Subscribe >> Deal exit on
Dec. 14, 2020
Deal entry on
Dec. 14, 2020
19.02%Expected margin
68.25% successful of 63 deals
$ 216.20 Last close price
at 29-oct-2021


Model's trade recommendations No return for period yet

-5.93% Annual return

$38.77B Market Cap

β 0.97  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period
52wk return 12.43%
52wk Range
Sortino ratio -0.27
Sharpe ratio -0.25
Norm. RMSE 19.52%
Downside risk 16.81%
Volatility 0.00%
  • 0.50 (0.63%) Div (Yield)
  • BUY Analysts consensus recommendation

Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Zoetis Inc. (ZTS) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for ZTS model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for ZTS.

Model is being retrained on a regular basis.

Float 484M
P/E 30.50
Shares Outstanding 485M
% Held by Insiders 0.35%
% Held by Institutions 92.60%
EPS (last reported FY) $2.40
EPS (last reported Q) $0.75
EPS, estimated (last reported Q) $0.70
Total revenues $5 B
Net income $1 B